Skip to main content

OneMedNet Adds 2.7M Annual Cardiovascular Studies, Expanding Network

MINNEAPOLIS, Aug. 20, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD), announced the addition of 85 cardiovascular centers and data sources, expanding its Cardiovascular network thereby positioning OneMedNet as one of the largest providers for Cardiovascular Real-World data.

Cardiovascular diseases (CVDs) remain the world’s leading cause of death, responsible for approximately 19.8 million deaths in 2022, accounting for roughly 32% of all global mortality1. Economically, the burden is staggering: CVD drives an estimated $320 billion annually in the United States alone, and more than $1 trillion globally each year in direct healthcare costs and lost productivity2.

Such pervasive health and financial pressures make OneMedNet’s enriched multimodal cardiovascular data network ideally suited for pharmaceutical and insurance sectors. For drug developers, this real-time, expansive data offers deeper insights into disease progression, treatment responses, and outcomes—fueling more efficient, evidence-based R&D and accelerating the development of novel therapeutics.

This expansion enhances OneMedNet’s network, delivering de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECG) at unprecedented scale and clinical depth to life sciences companies, AI developers, and medical device manufacturers, with data that is continually updated to reflect the latest clinical insights and advancements.

The addition of these new sites solidifies OneMedNet’s position as the premier source for high-quality, regulatory-grade cardiovascular RWD, fueling innovation, supporting clinical evidence generation, and improving patient outcomes through the most robust ecosystem in the industry.

“By combining de-identified cardiovascular imaging, structured reports, and ECG signals from this vast network, we’re providing real-world clinical insights that accelerate innovation in diagnostics, therapeutics, and AI model development. This is the clinically rich, longitudinal data the industry has been demanding—and we’re delivering it at scale, with continual updates ensuring the most current and relevant information,” said Aaron Green, President and CEO of OneMedNet.

  1. World Health Organization Cardiovascular Disease – https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29
  2. World Heart Federation 2025 Report – https://world-heart-federation.org/resource/world-heart-report-2025/

About OneMedNet Corporation

OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,750 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. We base these forward-looking statements on our current expectations and projections about future events, which we derive from the information presently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.

OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.